Francisco Idalsoaga MD
@FcoIdalsoaga
Followers
398
Following
938
Media
67
Statuses
717
Gastroenterologist /Clinical Researcher @WesternU @FacMedicinaUC, Founder Salud Calle Foundation @SaludCalle. 🇨🇱🇨🇦
London, Ontario
Joined June 2012
A meta-analysis shows that in liver disease due to alcohol use, psychosocial therapy reduces return-to-drinking by ~50%: 👉 Treating AUD in CLD is NOT just about prescribing pills. 👉 Psychosocial therapy + pharmacotherapy = best outcomes. Offer both ! https://t.co/Enl66kRowV
2
33
60
🚨 Fresh review out from @KaanthiRama @vinayjaha! We’re moving beyond AST/ALT in ALD. This paper maps the shift toward precision ALD: from genetics 🧬 to the gut microbiome 🧫 and endocrine signaling❗️Much-needed and very interesting read. Check it out 👇
1
3
7
Check out our review on novel biomarkers for 🍷liver disease in @CMH_journal From ELF, Pro-C3 & CK-18 to genetics, microbiome & multi-omics 🧬 Practical visuals for busy clinicians included 🩺 ✨ team @juanpabloarab @MarcoArreseMD @LuisAntonioDiaz @BlaneyMD @FcoIdalsoaga
Excellent work on this review of novel biomarkers for ALD and clinical implications, including risk stratification. A must-read for those caring for patients with ALD. @KaanthiRama @vinayjaha @FcoIdalsoaga @LuisAntonioDiaz @MarcoArreseMD @juanpabloarab
https://t.co/5eIik1IKGJ
0
8
36
Delivered my first oral presentation at the VCU Cancer Research Conference. Grateful to my mentors @juanpabloarab @FcoIdalsoaga and my amazing colleagues @Ximena_Parraga_ @kavin_parmar @dami_gu @OmarAdnanA for all the support and encouragement. @VCU_Liver @VCUMassey
5
5
56
Loved every moment at #TLM2025 @AASLDtweets ! Fantastic sessions and great networking. So thankful to be a part of this awesome community! #LiverLovers
#MariachiLiverTeam
5
6
41
If you 🩷 liver➕specifically ALD, you need to follow @ASRG_Liver A wonderful, productive, and passionate group. Follow to stay up to date on the latest and greatest in ALD! @juanpabloarab @LuisAntonioDiaz @FcoIdalsoaga @MarcoArreseMD @AdelinaHorhat @vinayjaha and many more 🤩
0
6
19
Incretin based therapies post bariatric surgery are effective 💉 Kudos to @butrosfakhoury for leading our high-impact study 👏 Stay tuned for more on this 📻 @VCU_Liver #TLM2025
@AASLDtweets @AASLDPresident @AASLDFoundation @AmCollegeGastro @AmerGastroAssn @INASL_Liver @EASLedu
1
4
28
👏 Incredible presentation by @butrosfakhoury at #TLM25! lncretin-based therapies (like semaglutide) are linked to a significantly lower risk of new-onset alcohol use disorder after bariatric surgery ‼️Promising dual benefit in weight and addiction risk management. 🔬💡🗯️
Incretin based therapies post bariatric surgery are effective 💉 Kudos to @butrosfakhoury for leading our high-impact study 👏 Stay tuned for more on this 📻 @VCU_Liver #TLM2025
@AASLDtweets @AASLDPresident @AASLDFoundation @AmCollegeGastro @AmerGastroAssn @INASL_Liver @EASLedu
0
3
8
Another 🔥 one from @FcoIdalsoaga at #TLM2025 Pre-transplant HCC = higher risk of post-transplant, non-HCC malignancy. Clean cohort, solid stats, and a reminder that LT follow-up has to think beyond recurrence. Amazing work!! 👏
0
3
10
Older adults with dementia can also have undiagnosed cirrhosis 🧠🤛 In geriatric clinic, 11% had elevated FIB-4 → possible advanced fibrosis. Adding FIB-4 to dementia care can help catch HE — a treatable cause of cognitive decline !! #TLM25 @VCUHealth Great work by @vinayjaha
0
1
21
Proud of our team @Ximena_Parraga_ presenting her work at #TLM25 🙌 we showed data on how therapeutic plasma exchange can modify bile acid composition — giving clues to mechanisms and maybe future treatment targets !!! - Exactly the kind of translational hepatology we need.
0
3
15
Short-term mortality in severe AlcHep remains high! Our systematic review & meta-analysis presented at #TLM25 shows 28d ≈26.8%, 60d ≈35.1%, 90d ≈43.7%! We need better treatments and faster, standardized care! #LiverTwitter
@FcoIdalsoaga @juanpabloarab
0
2
8
@DrLoomba @BlaneyMD @DrHuangDQ @MarcoArreseMD @AASLDtweets @juanpabloarab @DeepikaDevuniMD Finally, Prof. @juanpabloarab is comparing the natural history of SLD subtypes. Alcohol, metabolic risk factors and genetic risk can impact, being ALD at the highest risk of liver-related events #TLM2025 @AASLDtweets @FcoIdalsoaga @MarcoArreseMD @rabataller @geneyim
1
5
9
Starting the ALD SIG poster highlights at #TLM2025 with exciting data on alcohol, PEth interpretation, and liver disease! @AASLDtweets @juanpabloarab @DeepikaDevuniMD @geneyim @FcoIdalsoaga @CristiLlorente
0
3
23
🗣️Integrated care of AUD and ALD is 🔑. One cannot treat ALD without treating the underlying alcohol use. To learn more about integrated ALD/AUD care and the gold standard of ALD treatment, please read our new 📜, 🔥 off the press! https://t.co/uRJH2Hrrl4
3
20
68
New insights on assessing LIVER FIBROSIS with NON-INVASIVE TESTS, just released by @NEJM: - Key techniques & thresholds. - Practical algorithms & actionable steps. https://t.co/KkPHLNaLh3
6
67
256
Our RS-MA on placebo rates in MASLD clinical trials included 127 studies comprising more than 6,800 patients and found that: ✅ The placebo response in MASLD ranged from 4% to 30%. ❗️ It depended on the outcomes assessed @juanpabloarab @LuisAntonioDiaz
https://t.co/hjcLE0mf8O
0
2
3
In our recent systematic review and meta-analysis: @juanpabloarab @LuisAntonioDiaz ‼️ Short-term mortality in severe alcohol-associated hepatitis remains high and has not improved in recent decades ✅ Novel and effective therapies are urgently needed
34 studies including 1586 patients with severe alcohol-associated hepatitis found pooled mortality rates of 26.8% at 28 days, 35.1% at 60 days, and 43.7% at 90 days. Read the full meta-analysis 'open access' via https://t.co/l7Tc8IcvQm
#livertwitter #sAH
0
2
6
1 in 30 kids in the U.S. will experience homelessness this year. Family homelessness isn’t rare—it’s just hidden in cars, motels, and doubled-up homes. It’s time to make children and parents visible in the fight for housing. https://t.co/t876ObLdAm
invisiblepeople.tv
Family homelessness is a hidden crisis in America, driven by skyrocketing housing costs and systemic failures.
0
3
4